Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (��tampar Martina) .

41 - 50 / 172
First pagePrevious page12345678910Next pageLast page
41.
Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients : a pilot study
Nežka Hribernik, Daniel T. Huff, Andrej Studen, Katarina Zevnik, Žan Klaneček, Hamid Emamekhoo, Katja Škalič, Robert Jeraj, Martina Reberšek, 2022, original scientific article

Abstract: Purpose: To develop quantitative molecular imaging biomarkers of immune-related adverse event (irAE) development in malignant melanoma (MM) patients receiving immune-checkpoint inhibitors (ICI) imaged with 18F-FDG PET/CT. Methods: 18F-FDG PET/CT images of 58 MM patients treated with anti-PD-1 or anti-CTLA-4 ICI were retrospectively analyzed for indication of irAE. Three target organs, most commonly affected by irAE, were considered: bowel, lung, and thyroid. Patient charts were reviewed to identify which patients experienced irAE, irAE grade, and time to irAE diagnosis. Target organs were segmented using a convolutional neural network (CNN), and novel quantitative imaging biomarkers - SUV percentiles (SUVX%) of 18F-FDG uptake within the target organs - were correlated with the clinical irAE status. Area under the receiver-operating characteristic curve (AUROC) was used to quantify irAE detection performance. Patients who did not experience irAE were used to establish normal ranges for target organ 18F-FDG uptake. Results: A total of 31% (18/58) patients experienced irAE in the three target organs: bowel (n=6), lung (n=5), and thyroid (n=9). Optimal percentiles for identifying irAE were bowel (SUV95%, AUROC=0.79), lung (SUV95%, AUROC=0.98), and thyroid (SUV75%, AUROC=0.88). Optimal cut-offs for irAE detection were bowel (SUV95%>2.7 g/mL), lung (SUV95%>1.7 g/mL), and thyroid (SUV75%>2.1 g/mL). Normal ranges (95% confidence interval) for the SUV percentiles in patients without irAE were bowel [1.74, 2.86 g/mL], lung [0.73, 1.46 g/mL], and thyroid [0.86, 1.99 g/mL]. Conclusions: Increased 18F-FDG uptake within irAE-affected organs provides predictive information about the development of irAE in MM patients receiving ICI and represents a potential quantitative imaging biomarker for irAE. Some irAE can be detected on 18F-FDG PET/CT well before clinical symptoms appear.
Keywords: melanoma, malignant melanoma, immune-checkpoint inhibitors, molecular imaging biomarkers
Published in DiRROS: 07.09.2022; Views: 483; Downloads: 145
.pdf Full text (9,65 MB)

42.
Izbrane teme iz internistične onkologije za zdravnike družinske medicine, Ljubljana, junij 2022
2022, proceedings of peer-reviewed scientific conference contributions (domestic conferences)

Keywords: internistična onkologija, družinska medicina, onkološko zdravljenje
Published in DiRROS: 30.08.2022; Views: 554; Downloads: 340
.pdf Full text (56,64 MB)

43.
Dnevnik zdravljenja z zdravilom regorafenib
Janja Ocvirk, Martina Reberšek, Neva Volk, Tanja Mesti, Marko Boc, Marija Ignjatović, Nežka Hribernik, 2022, dictionary, encyclopaedia, lexicon, manual, atlas, map

Keywords: kemoterapija, rak debelega črevesa in danke, gastrointestinalni tumorji
Published in DiRROS: 14.07.2022; Views: 748; Downloads: 197
.pdf Full text (2,48 MB)

44.
45.
Adjuvantno sistemsko zdravljenje kožnega melanoma : Elektronski vir
Martina Reberšek, 2022, published scientific conference contribution

Keywords: melanom, rak kože, sistemsko zdravljenje
Published in DiRROS: 08.04.2022; Views: 534; Downloads: 156
.pdf Full text (543,87 KB)

46.
Melanom in nemelanomski kožni raki : uredniki zbornika Marko Boc ... [et al.]
2022, proceedings of professional or unreviewed scientific conference contributions

Keywords: rak kože, melanom, nemelanomski kožni raki
Published in DiRROS: 08.04.2022; Views: 653; Downloads: 462
.pdf Full text (39,15 MB)
This document has many files! More...

47.
Dynamic contrast-enhanced MRI in malignant pleural mesothelioma : prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy
Martina Vivoda Tomšič, Peter Korošec, Viljem Kovač, Sotirios Bisdas, Katarina Šurlan Popović, 2022, original scientific article

Abstract: The malignant pleural mesothelioma (MPM) response rate to chemotherapy is low. The identification of imaging biomarkers that could help guide the most effective therapy approach for individual patients is highly desirable. Our aim was to investigate the dynamic contrast-enhanced (DCE) MR parameters as predictors for progression-free (PFS) and overall survival (OS) in patients with MPM treated with cisplatin-based chemotherapy. Methods: Thirty-two consecutive patients with MPM were enrolled in this prospective study. Pretreatment and intratreatment DCE-MRI were scheduled in each patient. The DCE parameters were analyzed using the extended Tofts (ET) and the adiabatic approximation tissue homogeneity (AATH) model. Comparison analysis, logistic regression and ROC analysis were used to identify the predictors for the patient's outcome. Results: Patients with higher pretreatment ET and AATH-calculated Ktrans and ve values had longer OS (P≤.006). Patients with a more prominent reduction in ET-calculated Ktrans and kep values during the early phase of chemotherapy had longer PFS (P =.008). No parameter was identified to predict PFS. Pre-treatment ET-calculated Ktrans was found to be an independent predictive marker for longer OS (P=.02) demonstrating the most favourable discrimination performance compared to other DCE parameters with an estimated sensitivity of 89% and specificity of 78% (AUC 0.9, 95% CI 0.74-0.98, cut off > 0.08 min-1). Conclusions: In the present study, higher pre-treatment ET-calculated Ktrans values were associated with longer OS. The results suggest that DCE-MRI might provide additional information for identifying MPM patients that may respond to chemotherapy.
Keywords: cisplatin, magnetic resonance imaging, mesothelioma
Published in DiRROS: 06.04.2022; Views: 1098; Downloads: 479
.pdf Full text (1,55 MB)
This document has many files! More...

48.
Vloga radiomike v napovedovanju učinkovitosti zdravljenja z imunoterapijo pri bolnikih z rakom pljuč
Martina Vrankar, Damijan Valentinuzzi, Nina Boc, Mojca Unk, 2021, published scientific conference contribution

Keywords: rak pljuč, radiomika, imunoterapija
Published in DiRROS: 04.04.2022; Views: 551; Downloads: 185
.pdf Full text (293,52 KB)

49.
50.
Naše izkušnje kombinirane terapije pri bolnikih z nedrobnoceličnim pljučnim rakom stadija III
Martina Vrankar, 2021, published professional conference contribution

Keywords: imunoterapija, radioterapija, onkološko zdravljenje
Published in DiRROS: 29.03.2022; Views: 426; Downloads: 214
.pdf Full text (104,04 KB)
This document has many files! More...

Search done in 0.36 sec.
Back to top